Know face complications in gynaecological surgery helps control health expenditure.

– during the surgery, gynecological surgeons may face complications not belonging to their area and requiring intestinal surgeryurological or vascular, whose handling requires specific training

-El I course of management of complications in Gynecologic Surgery offers for the first time to gynecologists learn to successfully resolve these difficulties, know the basic forms of action and take preventive action

Madrid, may 2012.- vascular, Urological or intestinal complications are some of the problems which can be found the surgeon specialist in Gynecology during surgery. To successfully resolve these complications do not belong to your area, specific training, is essential so that you know how to deal with them and prevent them. This training need arises the I course of management of complications in Gynecologic Surgery, which has had as objective to give the opportunity for the first time to General gynecologists improve and gain experience in non gynaecological surgery. A total of 60 specialists from all Spain, of whom more than half are heads of service, gathered on 20 April in Madrid at this meeting which had the support of Takeda.

Dr. Luis Chiva, head of Department of Gynecology Oncology of the Hospital MD Anderson Cancer Center of Madrid and one of the speakers at the meeting, says that this formation is essential ” for gynaecologists as it is a very broad specialty that does not have a rotation established by the various specialties of surgery ”, which is why in the 4 years of specialization does not give time to train the gynecologists in intestinal surgery, Urological surgery and vascular surgery ”. The course is supplemented this training teaching facing simple complications and to define the criteria to know when it is necessary to notify a specialist.

This initiative takes on special relevance in the current health care environment, said Dr. Chiva, the percentage of complications is one of the most important health indicators which indicen spending ”. Surgeons who have fewer complications spent far less, and logically the degree of satisfaction of individuals subject to interventions is infinitely greater ”, says the doctor. On a practical level, the complications in gynecological surgeries occur in less than 2% of the cases.

The first tried the complications of intestinal origin, mainly the small and thick intestine. Lesions in the wall of the intestine that can occur for various reasons (infections, endometriosis and adhesions …), should be recognized and addressed properly, because otherwise could produce a peritonitis which can assume a reoperation ”, explains Dr. Chiva. The course was explained to participants how to carry out surgical proceedings such as intestinal anastomosis or stomata.

The second block tried vascular complications, in particular dealing with haemorrhage and severe bleeding by vascular damage and how is the repair. also, explained to the attendees how to use sponges that allow a sealed in case of bleeding important to combat the intraoperative bleeding.

Finally, taught how to deal with possible injuries of the urological tract. The uterus and ovaries are in contact with the entry of the ureters and the bladder, and may in certain circumstances these be damaged, leading to Fistula involving the loss of urine with the consequent incontinence ”, says the doctor. It is therefore very important to put in place preventive measures to avoid this circumstance, learn basic forms of action before these difficulties and know how to fix it in intraoperative way.

Dr. Chiva has been responsible for provide talks together with Dr. Fernando Lapuente, of the Department of General Surgery in the Hospital of Madrid throughout the day at the Hotel Eurostars Madrid Tower.

About Takeda Pharmaceutical Spain

As the largest pharmaceutical company of Japan and one of the leading companies of the industry, the Mission of Takeda is directing its efforts to improve the health of patients worldwide through leading innovation in the field of medicine. The company has a commercial presence in over 70 countries, with particular strength in Asia, North America, Europe and emerging markets of rapid growth such as Latin America, Russia-CIS and China. Takeda occupies the position number 12 in the world ranking of pharmaceutical companies, the number 14 in the BRIC countries (Brazil, Russia, India and China) and 18 in Europe. The commercial presence of Takeda mainly covers the therapeutic areas of metabolic diseases, Gastroenterology, Oncology, cardiovascular health, diseases of the central nervous system, inflammatory and immune disorders, respiratory diseases and pain management.